To determine the clinical significance of viral quasispecies heterogeneity, 59 patients with chronic hepatitis C were studied using singlestranded conformational polymorphism (SSCP) analysis of the HCV E2 hypervariable region 1 (HVRI); of these, 48 were subsequently treated with interferon-a. The SS
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C
β Scribed by Alan Lee Rothman; Chihiro Morishima; Herbert L. Bonkovsky; Stephen J. Polyak; Ranjit Ray; Adrian M. Di Bisceglie; Karen L. Lindsay; Peter F. Malet; Ming Chang; David R. Gretch; Daniel G. Sullivan; Atul K. Bhan; Elizabeth C. Wright; Margaret James Koziel
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 174 KB
- Volume
- 41
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
The relationships among host immune and viral factors and the severity of liver disease due to hepatitis C virus (HCV) are poorly understood. Previous studies have focused on individual components of the immune response to HCV, often in relatively small numbers of patients. We measured HCV-specific lymphoproliferation (LP), intrahepatic cytotoxic T lymphocyte (CTL), and neutralizing antibody (NA) responses and HCV quasispecies (QS) diversity and complexity in a large cohort of subjects with advanced liver fibrosis (Ishak stages 3-6) on entry into the HALT-C (Hepatitis C Antiviral Long-term Treatment against Cirrhosis) trial. We correlated LP, CTL, NA, and QS results with clinical characteristics, including serum alanine aminotransferase (ALT), HCV RNA level, HCV genotype, and hepatic histopathology. LP, CTL, and NA responses were detected in 37%, 22%, and 22% of subjects tested, respectively. The only association that was statistically significant was higher mean serum ALT values in patients with detectable HCV-specific CTL responses (P = .03). In conclusion, immune responses to HCV and viral diversity showed little relationship to clinical or histological features at a single time point in this selected population of patients with advanced chronic hepatitis C for whom prior interferon treatment had failed.
π SIMILAR VOLUMES
To clarify the virological differences in patients with chronic hepatitis C virus (HCV) infection with and without liver damage, we assessed HCV markers in 306 patients from a rural area of Japan. Genotypes of HCV RNA were determined by polymerase chain reaction, and levels of RNA were determined by
autoantibodies (anti-nuclear [ANA], 10 anti-smooth muscle To investigate the factors that may confer susceptibil- [SMA], 11 anti-GOR, 12 anti-liver, kidney microsomes [LKM] ity or protection to hepatitis C virus (HCV) infection and antibodies 13 ). Despite these observations, however, it reto HCV-a
We systematically reviewed the literature on the extent to which population characteristics or clinical features predict groups of individuals likely to develop advanced liver disease or die from chronic infection with hepatitis B virus (HBV). We searched Medline to include studies with reported cir
Frequent coinfection of surface antigen-negative hepatitis B virus (silent HBV) in hepatitis C virus (HCV)-associated chronic liver disease (CLD) has been reported. The clinical and virological significance of silent HBV infection was investigated in 65 patients with HCV-associated CLD who subsequen
## Abstract In most patients, chronic hepatitis C virus (HCV) infection persists despite antiviral treatment with interferonβalpha (IFNβΞ±) and ribavirin. The aim of the study was to determine whether HCV could evade cellular immune responses through mutations within T cell epitopes. Viral sequences